Translational biology of osteosarcoma

Maya Kansara,Michele W. Teng,Mark J. Smyth,David M. Thomas

DOI: https://doi.org/10.1038/nrc3838

IF: 78.5

2014-10-16

Nature Reviews Cancer

Abstract:Key PointsOsteosarcomas are rare malignancies of bone, affecting primarily children and adolescents. Patients are typically treated with surgery and intensive adjuvant chemotherapy. The 5-year survival rate for recurrent or metastatic osteosarcoma is less than 25%.Bone has a highly specialized microenvironment. Crosstalk between osteoblasts, the cell lineage from which osteosarcoma arises, and monocyte-derived osteoclasts, occurs via signalling molecules that, in many cases, are linked to immune biology.Osteosarcomas are characterized by high levels of genomic instability. Recently, novel mutation patterns have been observed, including chromothripsis and kataegis. Few recurrent, therapeutically targetable mutations have been found.Therapeutic strategies targeting oncogenic kinases have been disappointing, while strategies targeting the osteoclast using denosumab and bisphosphonates are being evaluated.Immune strategies show promise. The immune adjuvant, mifamurtide is the most substantial therapeutic advance in osteosarcoma in the past 10 years.Evidence from preclinical studies suggests that immune checkpoint blockade inhibitors may be useful in the treatment of this disease.

oncology